3,903 Cencora, Inc. $COR Shares Purchased by Provenance Wealth Advisors LLC

05 Nov 2026, 05:53 by Jessica Moore · The Cerbat Gem

Provenance Wealth Advisors LLC lifted its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 24,393.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,919 shares of the company’s stock after purchasing an additional 3,903 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Cencora were worth $1,177,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Cencora during the second quarter worth about $5,154,136,000. Bank of America Corp DE raised its position in shares of Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after buying an additional 267,318 shares in the last quarter. Amundi raised its position in shares of Cencora by 43.5% in the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after buying an additional 676,066 shares in the last quarter. Carmignac Gestion raised its position in shares of Cencora by 58.7% in the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after buying an additional 646,112 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Cencora by 2.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,549,047 shares of the company’s stock worth $486,576,000 after acquiring an additional 35,569 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.38% of the stock is currently owned by insiders.

Cencora Stock Up 4.0%

Shares of NYSE COR opened at $354.20 on Thursday. The company has a 50 day simple moving average of $324.60 and a 200 day simple moving average of $317.44. The firm has a market cap of $67.59 billion, a PE ratio of 26.31, a price-to-earnings-growth ratio of 1.74 and a beta of 0.58. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.08. The firm had revenue of $88.35 billion during the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.84 EPS. On average, research analysts forecast that Cencora, Inc. will post 17.88 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is a boost from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is 17.83%.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

Positive Sentiment: Fiscal Q4 adjusted EPS of $4.66 beat the $4.58 consensus, while revenue of $88.35 billion topped estimates of $87.95 billion and rose 5.5% year over year. Cencora also reported higher earnings than a year earlier. Article: Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
Positive Sentiment: The company forecast fiscal 2027 EPS of $19.40–$19.75, with specialty growth supporting its outlook. The guidance gives investors an indication of continued earnings growth. Article: Cencora outlines fiscal 2027 EPS outlook
Positive Sentiment: Cencora raised its quarterly dividend 10%, from $0.60 to $0.66 per share, signaling increased cash returns to shareholders. Company dividend information
Neutral Sentiment: Cencora is reorganizing its reporting structure to improve focus and visibility. The change may help execution, though the new structure itself does not establish a near-term financial benefit. Article: Cencora announces new organizational and reporting structure
Neutral Sentiment: Management’s earnings-call discussion was broadly positive but included mention of headwinds; the provided coverage does not detail their size or likely effect on results. Article: Cencora earnings call highlights specialty growth and headwinds

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a $330.00 price objective on shares of Cencora in a research note on Tuesday, September 8th. Wells Fargo & Company raised their target price on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Citigroup reaffirmed a “buy” rating on shares of Cencora in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Argus boosted their price target on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $368.38.

Get Our Latest Analysis on Cencora

Cencora Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.